The British journal of surgery · 2005
Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Landheer M L E A, Steffens M G, Klinkenbijl J H G, Westenberg A H, Oyen W J G
Аннотация
BACKGROUND: The aim of this prospective study was to evaluate the role of fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging of high-risk women with primary or recurrent breast cancer.
METHODS: FDG-PET was performed in 42 women with a primary breast cancer and unfavourable characteristics, or who had a suspected relapse. FDG-PET and conventional staging methods were compared. In case of abnormality on FDG-PET, confirmation was always attempted.
RESULTS: Increased uptake was found in five of 17 women with a primary cancer. In the 25 women with a suspected relapse, FDG-PET showed increased uptake in 43 areas, 22 correctly confirming the area of suspected relapse and 21 indicating other sites of metastases. Compared with conventional imaging, FDG-PET revealed additional (confirmed) lesions in two women with primary cancers and three with relapse. Patient management was changed for five women.
CONCLUSION: FDG-PET is a sensitive diagnostic method for the detection of distant metastatic disease. Its exact role in women with breast cancer remains to be defined.
METHODS: FDG-PET was performed in 42 women with a primary breast cancer and unfavourable characteristics, or who had a suspected relapse. FDG-PET and conventional staging methods were compared. In case of abnormality on FDG-PET, confirmation was always attempted.
RESULTS: Increased uptake was found in five of 17 women with a primary cancer. In the 25 women with a suspected relapse, FDG-PET showed increased uptake in 43 areas, 22 correctly confirming the area of suspected relapse and 21 indicating other sites of metastases. Compared with conventional imaging, FDG-PET revealed additional (confirmed) lesions in two women with primary cancers and three with relapse. Patient management was changed for five women.
CONCLUSION: FDG-PET is a sensitive diagnostic method for the detection of distant metastatic disease. Its exact role in women with breast cancer remains to be defined.